Compare
Acrivon Therapeutics, Inc. vs Citius Pharmaceuticals, Inc. vs Silence Therapeutics plc vs Zomedica Corp.
| Latest fiscal year | Acrivon Therapeutics, Inc. ACRV | Citius Pharmaceuticals, Inc. CTXR | Silence Therapeutics plc SLN | Zomedica Corp. ZOMDF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $559.0K | $32.03M |
| Revenue growth (YoY) | n/a | n/a | -98.7% | +17.4% |
| Gross margin | n/a | n/a | 61.5% | 67.7% |
| Operating margin | n/a | n/a | n/m | -263.4% |
| Net margin | n/a | n/a | n/m | -255.6% |
| Net income | -$77.91M | -$39.74M | -$88.61M | -$81.86M |
| EPS (Diluted) | -$2.02 | -$3.38 | -$0.63 | -$0.08 |
| Operating cash flow | -$63.66M | -$26.55M | -$62.27M | -$17.65M |
| Free cash flow | -$65.33M | n/a | -$62.33M | -$18.22M |
| Cash & equivalents | $41.50M | $4.25M | $11.28M | $9.02M |
| Total assets | $129.72M | $130.94M | $131.44M | $127.04M |
| Total liabilities | $17.20M | $53.41M | $69.14M | $11.64M |
| Shareholders' equity | $112.52M | $67.55M | $62.30M | $115.40M |
| Return on year-end equity | -69.2% | -58.8% | -142.2% | -70.9% |
| Shares outstanding | 31.65M | 18.07M | 141.70M | 979.95M |
Revenue, most recent five fiscal years
| Fiscal year | Acrivon Therapeutics, Inc. | Citius Pharmaceuticals, Inc. | Silence Therapeutics plc | Zomedica Corp. |
|---|---|---|---|---|
| Latest | n/a | $90.0K Ended 2022-09-30 | $559.0K Ended 2025-12-31 | $32.03M Ended 2025-12-31 |
| 1 year earlier | n/a | $90.0K Ended 2021-09-30 | $43.26M Ended 2024-12-31 | $27.29M Ended 2024-12-31 |
| 2 years earlier | n/a | $90.0K Ended 2020-09-30 | $31.64M Ended 2023-12-31 | $25.19M Ended 2023-12-31 |
| 3 years earlier | n/a | $90.0K Ended 2019-09-30 | $21.66M Ended 2022-12-31 | $18.93M Ended 2022-12-31 |
| 4 years earlier | n/a | $75.0K Ended 2018-09-30 | n/a | $4.13M Ended 2021-12-31 |